FI4168033T3 - CEBP-beta -antagonistin anto ja käyttötavat - Google Patents

CEBP-beta -antagonistin anto ja käyttötavat

Info

Publication number
FI4168033T3
FI4168033T3 FIEP21828902.3T FI21828902T FI4168033T3 FI 4168033 T3 FI4168033 T3 FI 4168033T3 FI 21828902 T FI21828902 T FI 21828902T FI 4168033 T3 FI4168033 T3 FI 4168033T3
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
use according
patient
intended
administration
Prior art date
Application number
FIEP21828902.3T
Other languages
English (en)
Finnish (fi)
Inventor
Barry Kappel
Gene Merutka
Jimmy Rotolo
Robert E Michel
Alice Susannah Bexon
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Application granted granted Critical
Publication of FI4168033T3 publication Critical patent/FI4168033T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP21828902.3T 2020-06-21 2021-06-21 CEBP-beta -antagonistin anto ja käyttötavat FI4168033T3 (fi)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063041991P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041990P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202163172560P 2021-04-08 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (1)

Publication Number Publication Date
FI4168033T3 true FI4168033T3 (fi) 2026-04-07

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21828902.3T FI4168033T3 (fi) 2020-06-21 2021-06-21 CEBP-beta -antagonistin anto ja käyttötavat

Country Status (17)

Country Link
US (1) US20230218717A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7880618B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230027054A (cg-RX-API-DMAC7.html)
CN (1) CN115768458A (cg-RX-API-DMAC7.html)
AU (1) AU2021297172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022025880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180559A1 (cg-RX-API-DMAC7.html)
DK (1) DK4168033T3 (cg-RX-API-DMAC7.html)
ES (1) ES3066151T3 (cg-RX-API-DMAC7.html)
FI (1) FI4168033T3 (cg-RX-API-DMAC7.html)
IL (1) IL299104A (cg-RX-API-DMAC7.html)
MX (1) MX2022016478A (cg-RX-API-DMAC7.html)
NZ (1) NZ795026A (cg-RX-API-DMAC7.html)
PT (1) PT4168033T (cg-RX-API-DMAC7.html)
WO (1) WO2021262604A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202213167B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119997967A (zh) * 2022-10-07 2025-05-13 智慧疗法有限公司 C/EBP-β拮抗剂和免疫调节剂的使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
EP4694911A2 (en) * 2023-04-13 2026-02-18 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228642A (zh) * 2013-02-22 2016-01-06 纽约市哥伦比亚大学理事会 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
CA2983030A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
WO2018152446A2 (en) 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
PT3737399T (pt) 2018-01-03 2023-09-04 Sapience Therapeutics Inc Variantes do péptido atf5 e as respetivas utilizações
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Also Published As

Publication number Publication date
ES3066151T3 (en) 2026-05-11
EP4168033A4 (en) 2024-06-19
AU2021297172A1 (en) 2023-01-19
KR20230027054A (ko) 2023-02-27
EP4168033B1 (en) 2026-02-25
US20230218717A1 (en) 2023-07-13
IL299104A (en) 2023-02-01
PT4168033T (pt) 2026-03-24
BR112022025880A2 (pt) 2023-01-10
JP7880618B2 (ja) 2026-06-26
AU2021297172B2 (en) 2025-01-30
DK4168033T3 (da) 2026-05-11
MX2022016478A (es) 2023-02-01
ZA202213167B (en) 2026-03-25
CA3180559A1 (en) 2021-12-30
EP4168033A2 (en) 2023-04-26
NZ795026A (en) 2026-03-27
JP2023531683A (ja) 2023-07-25
WO2021262604A3 (en) 2022-02-17
WO2021262604A2 (en) 2021-12-30
CN115768458A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
US20250213515A1 (en) Methods for the treatment of glioblastoma multiforme
ES2836424T3 (es) Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
CN101669941B (zh) 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
Yan et al. Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
JP2006290863A (ja) 胃腸障害の治療
AU2017272098B2 (en) Improved therapeutic index of anti-immune checkpoint inhibitors using combination therapy comprising a PHY906 extract, a Scutellaria baicalensis GeorgI (S) extract or a compound from such extracts
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
JP2022551672A (ja) 乳癌治療法
JP2020536903A5 (cg-RX-API-DMAC7.html)
Yang et al. Pharmacological management of cancer pain: Advances in treatment strategies and drug delivery systems
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
US20260041676A1 (en) Combination Therapy
Bravo Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease
Aschhoff Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors
JP2000507207A (ja) 複合注射剤
TW201244732A (en) Ezatiostat for treating multiple myeloma
RU2013149175A (ru) Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы
Rosenberg et al. Oral biologics: the new wave for treating psoriasis
Caulin et al. 456 100% complete response to PEEL-224 in combination with PD-1 blockade in a syngeneic mouse model of colon cancer
RU2271831C1 (ru) Способ лечения онкологических заболеваний
RU2025107889A (ru) Комбинация талазопариба и энзалутамида при лечении метастатического кастрационно-резистентного рака предстательной железы
Baurain et al. A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced sarcoma
CN107375299A (zh) 一种积雪草酸的新用途及含积雪草酸的抗肿瘤药物组合